BRIEF—Alteogen grants option on NASH candidates

South Korea’s Alteogen has agreed a deal giving New Jersey, USA-based Lynkogen an exclusive option on novel proteins aimed at tackling NASH and other metabolic diseases.

Lynkogen will have exclusive worldwide rights, excluding Korea and emerging markets, to develop and commercialize the proteins, based on Alteogen’s NexPTM fusion technology.

Lynkogen CEO Arun Swaminathan said, “Non-Alcoholic Steatohepatitis (NASH) is a multi-faceted disease characterized by multiple triggers and there is a need for therapies that can address more than one trigger.”

“Alteogen’s GLP-1/A1AT fusion protein therapies simultaneously target the metabolic and inflammatory pathways and have the potential to provide patients with a unique option in the management of NASH and other complex metabolic disorders.”